What is the price-to-earnings ratio of Immunome?
The price-earnings ratio of Immunome is currently -1.16.
Immunome P/E 2024
Immunome P/E
-1.16
Ticker
IMNM
ISIN
US45257U1088
WKN
A2QD9D
As of Oct 25, 2024, Immunome's P/E ratio was -1.16, a 14.85% change from the -1.01 P/E ratio recorded in the previous year.
The Immunome P/E history
Immunome Aktienanalyse
What does Immunome do?
Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Immunome's P/E Ratio
The Price to Earnings (P/E) Ratio of Immunome is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Immunome's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Immunome is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Immunome’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Immunome stock
How has the price-earnings ratio of Immunome changed compared to last year?
The price-to-earnings ratio of Immunome has increased by 14.85% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Immunome high compared to other companies?
Yes, the price-to-earnings ratio of Immunome is high compared to other companies.
How does an increase in the price-earnings ratio of Immunome affect the company?
An increase in the price-earnings ratio of Immunome would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Immunome affect the company?
A decrease in the price-earnings ratio of Immunome would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Immunome?
Some factors that influence the price-earnings ratio of Immunome are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Immunome pay?
Over the past 12 months, Immunome paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunome is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunome?
The current dividend yield of Immunome is .
When does Immunome pay dividends?
Immunome pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunome?
Immunome paid dividends every year for the past 0 years.
What is the dividend of Immunome?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunome located?
Immunome is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunome kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunome from 10/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.
When did Immunome pay the last dividend?
The last dividend was paid out on 10/25/2024.
What was the dividend of Immunome in the year 2023?
In the year 2023, Immunome distributed 0 USD as dividends.
In which currency does Immunome pay out the dividend?
The dividends of Immunome are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunome
Our stock analysis for Immunome Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
